Abstract Number: 2324 • 2018 ACR/ARHP Annual Meeting
Predictors of Refracture in Patients with Hip Fragility Fracture
Background/Purpose: Hip fractures are associated with substantially elevated morbidity and mortality and thus represent a serious public health problem. The purpose of this study is…Abstract Number: 2811 • 2018 ACR/ARHP Annual Meeting
Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older
Background/Purpose: The risk of fracture increases with increasing age. Thus, it is important to understand efficacy and safety of osteoporosis treatments in elderly patients. In…Abstract Number: 2301 • 2018 ACR/ARHP Annual Meeting
Trend of Osteoporosis and Osteoporotic Fragility Fractures Among Select Autoimmune Rheumatologic Diseases: Results from National Inpatient Sample
Background/Purpose: Rheumatologic diseases (RDs) have been associated with an increased risk of osteoporosis (OP) and osteoporotic fractures, however, most patients do not receive diagnosis and…Abstract Number: 2302 • 2018 ACR/ARHP Annual Meeting
Forearm Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis
Background/Purpose: Wrist fractures are the most common fracture of the upper extremity and increase subsequent fracture risk in women with postmenopausal osteoporosis. Most wrist fractures…Abstract Number: 2303 • 2018 ACR/ARHP Annual Meeting
Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed By Alendronate
Background/Purpose: Abaloparatide (ABL) is a selective activator of the PTH1 receptor signaling pathway that stimulates bone formation. In the ACTIVE Phase 3 study, ABL significantly…Abstract Number: 1216 • 2017 ACR/ARHP Annual Meeting
Odontoid Fractures in the Elderly: An Unknown Osteoporotic Fracture?
Background/Purpose: Current WHO definition of osteoporosis excludes cervical fractures. However, in atraumatic odontoid fractures, mainly reported by orthopedic surgeons, bone status has not been described…Abstract Number: 1886 • 2017 ACR/ARHP Annual Meeting
Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis
Background/Purpose: Romosozumab (Romo) is a monoclonal antibody that binds sclerostin with a dual effect, increasing bone formation and decreasing bone resorption. In the primary analysis…Abstract Number: 1887 • 2017 ACR/ARHP Annual Meeting
Ten-Year Continued Nonvertebral Fracture Reduction in Postmenopausal Osteoporosis with Denosumab Treatment
Background/Purpose: Treatment with denosumab (DMAb) for 3 years significantly reduces the incidence of nonvertebral fractures (NVFx; Cummings NEJM 2009). While there are limited data describing…Abstract Number: 324 • 2016 ACR/ARHP Annual Meeting
A Placebo Controlled Trial of Vertebral Fill Technique Vertebroplasty for Acute Painful Osteoporotic Fracture (VAPOUR Trial)
Background/Purpose: Evaluation of efficacy and safety of percutaneous vertebral fill technique vertebroplasty in subjects with acute vertebral fracture (symptom duration less than six weeks) .…Abstract Number: 339 • 2016 ACR/ARHP Annual Meeting
Assessment of High-Resolution Peripheral Quantitative Computed Tomography Parameters and Markers of Bone Metabolism in Community-Dwelling Elderly with and without Vertebral Fractures – the Sao Paulo Ageing & Health Study
Background/Purpose: Bone mineral density(BMD) by dual X-ray absorptiometry(DXA) is currently standard clinical tool for predicting osteoporotic fracture. However, DXA doesn’t allow studying abnormalities that predict different…Abstract Number: 342 • 2016 ACR/ARHP Annual Meeting
Presence of Vertebral Fractures and Disc Disease in Post Menopausal Females with Height Loss As a Possible Screening Method for Osteoporosis
Background/Purpose: The presence of non-traumatic vertebral fracture can identify a patient who has clinical osteoporosis. However, approximately 75% of vertebral fractures are asymptomatic and as many…Abstract Number: 369 • 2015 ACR/ARHP Annual Meeting
Incidence of Fragility Hip Fractures over 10 Years (2004-13) in Three UK Centres with Reference to Local Fracture Prevention (‘fracture liaison’) Service Activity
Background/Purpose: Fracture Liaison Services systematically identify patients with fragility fracture and screen patients for osteoporosis and associated conditions and instigate evidence-based 'secondary' fracture prevention management.…Abstract Number: 372 • 2015 ACR/ARHP Annual Meeting
Prevalence of Atypical Fractures in a Tertiary Hospital
Background/Purpose: Actually, Biphosphonates are considered the first line treatment for osteoporosis. One of the side effects of the continuous treatment with these drugs is the…Abstract Number: 2232 • 2015 ACR/ARHP Annual Meeting
Risk of Osteoporotic Fractures with Use of Cyclooxygenase-2 Inhibitors
Background/Purpose: In animal models, cyclo-oxygenase (COX)-2 stimulates osteoclasts through prostaglandin E2 (PGE2). Therefore, non-steroidal anti-inflammatory drugs (NSAIDs) preferentially inhibiting COX-2 (ie-coxibs) should prevent bone…Abstract Number: 2800 • 2015 ACR/ARHP Annual Meeting
Bone Microarchitecture and Bone Strength in Patients with Primary Sjögren’s Syndrome: A Case-Control Study Using HR-pQCT
Background/Purpose: To evaluate bone mineral density (BMD), microarchitecture, strength and prevalence of vertebral fractures (VF) in primary Sjögren's syndrome (pSS).Methods: We evaluated 71 female pSS…